SpringWorks Therapeutics, Inc. SWTX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

57/100

4/7 Pass

SharesGrow Intrinsic Value

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

SpringWorks Therapeutics, Inc. (SWTX) generated $-175.6M in operating cash flow for fiscal year 2024. After capital expenditures of $4.45M, free cash flow was $-180.05M.

Free cash flow margin was -94% of revenue. Cash conversion ratio was 0.68x, suggesting some earnings are non-cash.

The company returned $8.44M in share buybacks to shareholders during the period.

Criteria supported by this page:

HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
MOAT (70/100, Pass) — $-180.05M (-94% FCF margin) supports a durable competitive advantage
INCOME (10/100) — Cash conversion ratio was 0.68x suggests some earnings are non-cash items

Overall SharesGrow Score: 57/100 with 4/7 criteria passed.

SharesGrow 7-Criteria Score

57/100

SG Score

View full scorecard →

✓

VALUE

90/100

Price-to-Earnings & upside

→ Valuation

✓

FUTURE

73/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

Proven by this page

✓

MOAT

70/100

Proven by this page

GROWTH

58/100

→ Income

✗

INCOME

10/100

→ Income

SpringWorks Therapeutics, Inc. Cash Flow History

Metric	TTM	FY2024	FY2023	FY2022	FY2021
Operating Cash Flow	$-165.43M	$-175.6M	$-222.8M	$-161.56M	$-127.88M
Capital Expenditure	$-8.9M	$-4.45M	$-7.39M	$-10.2M	$-2.02M
Free Cash Flow	$-174.33M	$-180.05M	$-230.18M	$-171.76M	$-129.89M